GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » 3-Year EPS without NRI Growth Rate

Hoth Therapeutics (Hoth Therapeutics) 3-Year EPS without NRI Growth Rate : 46.20% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics 3-Year EPS without NRI Growth Rate?

Hoth Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.31.

During the past 3 years, the average EPS without NRI Growth Rate was 46.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Hoth Therapeutics was 46.20% per year. The lowest was -33.80% per year. And the median was 24.10% per year.


Competitive Comparison of Hoth Therapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Hoth Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hoth Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



Hoth Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hoth Therapeutics  (NAS:HOTH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hoth Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Executives
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie director, officer: CEO and President C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns officer: Chief Scientific Officer 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes director 1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc 10 percent owner 725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr director C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner 10 percent owner 44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor 10 percent owner 750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern 10 percent owner 20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023